- Home
- PLMR vs AKRO Comparison
PLMR vs AKRO Comparison
Compare PLMR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLMR
- AKRO
- Stock Information
- Founded
- PLMR 2013
- AKRO 2017
- Country
- PLMR United States
- AKRO United States
- Employees
- PLMR N/A
- AKRO N/A
- Industry
- PLMR Property-Casualty Insurers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PLMR Finance
- AKRO Health Care
- Exchange
- PLMR Nasdaq
- AKRO Nasdaq
- Market Cap
- PLMR 3.3B
- AKRO 3.9B
- IPO Year
- PLMR 2019
- AKRO 2019
- Fundamental
- Price
- PLMR $123.21
- AKRO $44.72
- Analyst Decision
- PLMR Buy
- AKRO Strong Buy
- Analyst Count
- PLMR 8
- AKRO 8
- Target Price
- PLMR $156.43
- AKRO $80.38
- AVG Volume (30 Days)
- PLMR 279.2K
- AKRO 838.0K
- Earning Date
- PLMR 11-03-2025
- AKRO 08-08-2025
- Dividend Yield
- PLMR N/A
- AKRO N/A
- EPS Growth
- PLMR 49.38
- AKRO N/A
- EPS
- PLMR 5.68
- AKRO N/A
- Revenue
- PLMR $682,205,000.00
- AKRO N/A
- Revenue This Year
- PLMR $256.23
- AKRO N/A
- Revenue Next Year
- PLMR $18.70
- AKRO N/A
- P/E Ratio
- PLMR $21.67
- AKRO N/A
- Revenue Growth
- PLMR 52.98
- AKRO N/A
- 52 Week Low
- PLMR $85.00
- AKRO $21.34
- 52 Week High
- PLMR $175.85
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PLMR 45.05
- AKRO 36.92
- Support Level
- PLMR $120.25
- AKRO $43.08
- Resistance Level
- PLMR $126.57
- AKRO $46.18
- Average True Range (ATR)
- PLMR 3.26
- AKRO 1.62
- MACD
- PLMR 0.95
- AKRO -0.32
- Stochastic Oscillator
- PLMR 42.30
- AKRO 25.25
About PLMR Palomar Holdings Inc. Common stock
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.